Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A K Nowak

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2005
Cisplatin and gemcitabine in malignant mesotheliomaA K Nowak, M J Byrne
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Modified RECIST criteria for assessment of response in malignant pleural mesotheliomaM J Byrne, A K Nowak
Tissue Antigens|May 9, 2009
Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesotheliomaM J McCoy, A K Nowak, R A Lake
Lancet (London, England)|May 6, 1995
Darkroom hepatitis after exposure to hydroquinoneA K Nowak, K B Shilkin, G P Jeffrey
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 28, 2010
A prospective study of surgical patterns of care for high grade glioma in the current era of multimodality therapyA K Nowak, J E Maujean, M Jackson, et al.
Journal of Neuro-Oncology|December 15, 2010
Patient and caregiver perceptions of communication of prognosis in high grade gliomaE A Lobb, G K B Halkett, A K Nowak
The Cochrane Database of Systematic Reviews|October 19, 2007
Taxanes for adjuvant treatment of early breast cancerT Ferguson, N Wilcken, R Vagg, et al.
British Journal of Cancer|April 10, 2014
Response to comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'T M Meniawy, J Creaney, R A Lake, et al.
British Journal of Cancer|August 29, 2013
Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesotheliomaT M Meniawy, J Creaney, R A Lake, et al.
Oncogene|September 22, 2010
Harnessing the immune response to treat cancerH J Steer, R A Lake, A K Nowak, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2005
Cisplatin and gemcitabine in malignant mesotheliomaA K Nowak, M J Byrne
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2004
Modified RECIST criteria for assessment of response in malignant pleural mesotheliomaM J Byrne, A K Nowak
Tissue Antigens|May 9, 2009
Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesotheliomaM J McCoy, A K Nowak, R A Lake
Lancet (London, England)|May 6, 1995
Darkroom hepatitis after exposure to hydroquinoneA K Nowak, K B Shilkin, G P Jeffrey
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 28, 2010
A prospective study of surgical patterns of care for high grade glioma in the current era of multimodality therapyA K Nowak, J E Maujean, M Jackson, et al.
Journal of Neuro-Oncology|December 15, 2010
Patient and caregiver perceptions of communication of prognosis in high grade gliomaE A Lobb, G K B Halkett, A K Nowak
The Cochrane Database of Systematic Reviews|October 19, 2007
Taxanes for adjuvant treatment of early breast cancerT Ferguson, N Wilcken, R Vagg, et al.
British Journal of Cancer|April 10, 2014
Response to comment on 'Existing prognostic models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma'T M Meniawy, J Creaney, R A Lake, et al.
British Journal of Cancer|August 29, 2013
Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesotheliomaT M Meniawy, J Creaney, R A Lake, et al.
Oncogene|September 22, 2010
Harnessing the immune response to treat cancerH J Steer, R A Lake, A K Nowak, et al.
Pageof 3